Newsletter | March 7, 2022

03.07.22 -- New Pod Episodes: Gene Therapy with AAV Vectors and NK Cell Therapy Accessibility


Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters including our podcast series. Don’t forget to subscribe so you never miss an episode!

Voices From The Frontline Of Cell And Gene Discovery

REGENXBIO's Nina Hunter, Ph.D. Details The Accelerated Approval Pathway For Gene Therapies

REGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph.D., shares potential solutions to gene therapies' regulatory roadblocks and why the accelerated approval pathway is so pertinent.

Selecta Biosciences' Dr. Carsten Brunn On Gene Therapy With AAV Vectors

Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.


Regulatory Harmonization With Aurion Biotech's Dr. Daniela Drago

Dr. Daniela Drago, Chief Regulatory Officer at Aurion Biotech, shares her encyclopedic knowledge of the dynamic regulatory harmonization landscape. Along the way, she offers concrete advice on creating multijurisdictional regulatory efficiencies that will smooth your journey through the clinic and beyond.

Plant-Based Biologics With iBio's Randy Maddux

iBio is attempting to turn the CHO cell development paradigm on its ear with hydroponically-grown N. benthamiana. COO Randy Maddux says the approach could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. iBio is proving out the approach on candidates for oncological, infectious, and fibrotic diseases.

NK Cell Therapy Accessibility Ft. Dr. Kleanthis Xanthopoulos

Shoreline Biosciences CEO Kleanthis Xanthopoulos, Ph.D.shares on why the cell and gene immunotherapeutic market has underperformed to date, why he believes autologous is not the long-term path forward, and the safety and accessibility advantages he sees in an allogeneic-based, pluripotent stem cell approach.